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Abstract
Background:  Although intra-articular treatment with hyaluronic acid (HA) for symptomatic
osteoarthritis has become widely accepted in recent decades, the pattern of its use has seldom
been reported. We have explored the epidemiology of intra-articular HA treatment in Taiwan by
using the rich data source from nationwide insurance claims.
Methods: Taiwan's National Health Insurance (NHI), which covers 97% of inhabitants, offers
extensive hospitalisation and ambulatory care. We identified the beneficiaries aged 60 years and
older who received intra-articular HA within the NHI during 2004. The number of visits in which
HA was administered were analysed by patient's age and gender and by the physician's specialty and
practice site.
Results: Among the 73,410,777 ambulatory visits by 2,909,219 beneficiaries aged 60 years and
older in 2004, 35,782 (1.2%) patients received intra-articular HA treatment in 205,012 (0.3%) visits.
The highest prevalence of HA use was in the 70–79 year age group in both sexes. Women received
intra-articular HA treatment more frequently than men in all age groups, especially in the 60–69
and 70–79 year groups (1.6% vs. 0.5%, 2.2% vs. 1.0%, respectively). Most intra-articular HA
procedures were performed by orthopaedic surgeons (75.1%) and physical medicine and
rehabilitation physicians (15.2%), and at metropolitan hospitals (34.5%) and local community
hospitals (38.2%).
Conclusion: One out of 100 older patients in Taiwan received intra-articular HA treatment for
osteoarthritis of the knee during the course of the year. There were age-gender differences in use
of HA treatment. The completion rate of this treatment in our study was high, and thus intra-
articular HA might be a good alternative for patients for whom conventional treatment fails.
Further research is needed to examine the age-gender differences in use of intra-articular HA in
Taiwan.
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Background
Osteoarthritis of the knee is one of the leading causes of
disability among the older population. Beside functional
activities, it affects social relationships, body image and
emotional well-being [1,2]. In Western countries, 7–18%
of older people have symptomatic osteoarthritis of the
knee [3-5]. A population-based study in China also found
that symptomatic osteoarthritis of the knee occurs in 15%
of women and 6% of men aged 60 and older [6]. The pain
arising from osteoarthritis can be treated with several
kinds of drugs: paracetamol, non-steroidal anti-inflam-
matory drugs (NSAIDs), opioid analgesics, glucosamine
salt, chondroitin sulphate, diacerein, corticosteroids,
hyaluronic acid (HA) and capsaicin [7]. Most of these
drugs are for either oral or topical use; only corticosteroids
and HA can be administered intra-articularly. Because of
its viscoelasticity, HA may replace synovial fluid and pro-
tect the cartilage [8,9]. Intra-articular HA treatment for
osteoarthritis of the knee was approved by the US Food
and Drug Administration in 1997. In comparison with
NSAID and corticosteroid, the better tolerability and
fewer adverse effects of HA have made it widely accepted
in recent decades [8,10,11].
Most studies of intra-articular HA treatment examine its
effectiveness, but few consider the pattern of its use. In
Taiwan, HA treatment is reimbursed within the National
Health Insurance (NHI) system. Because complete NHI
claims are available in electronic form to researchers, we
could investigate the nationwide age- and sex-specific
prevalences and patterns of use of intra-articular HA in
Taiwan. Such information might elucidate the help-seek-
ing behaviour of patients and the preferences of physi-
cians in treating osteoarthritis of the knee, and could help
to allocate medical resources in health policy-making by
adjusting the reimbursement of this procedure in the
NHI.
Methods
Data sources
The NHI program in Taiwan started in 1995 and covered
22,134,270 beneficiaries (about 97% of inhabitants) at
the end of 2004 [12]. Since 1999, the Bureau of National
Health Insurance has released the claims data to the
National Health Research Institutes (NHRI) for research
use under the project of National Health Insurance
Research Database [13]. The electronic datasets contain
visit and prescription details, including the encrypted
identification numbers of beneficiaries and healthcare
facilities. With the approval of NHIRD for the research use
of anonymised datasets, the researchers must also sign a
user agreement of obeying the regulations of NHIRD and
acknowledging the NHIRD in their publications.
Since 1999, the NHI has reimbursed the mode of intra-
articular HA treatment for any patient whose osteoarthri-
tis of the knee is poorly responsive to conventional anal-
gesics but who is not yet eligible for total knee
arthroplasty. Physicians can decide by clinical judgement
whether patients meet the criteria for intra-articular HA
treatment. During the course of such treatment, the
patient cannot concomitantly receive NSAIDs, intra-artic-
ular corticosteroids or rehabilitation by physical modali-
ties. Only two courses are reimbursable for each patient in
a year. Each course includes 3–5 sessions of injection,
depending on the molecular weight of the HA product.
We obtained the dataset from the NHIRD containing the
complete claims of beneficiaries aged 60 and older in
2004.
Ten intra-articular HA products were available within the
NHI in 2004. Because physicians had to prescribe HA
products to the patients before each injection, we could
identify the patients directly from the prescription
records. Those who received no injection at that visit
would have no HA record.
Analyses
The annual age-sex prevalence of patients receiving intra-
articular HA treatment was analysed in three age groups:
60–69, 70–79, and 80 years and older. We further calcu-
lated the total number of intra-articular HA visits per
patient during the year. The data were also stratified by the
specialties of physicians and the accreditation level of the
healthcare facilities. There were 24 specialties and 22 sub-
specialties. We arbitrarily grouped the practitioners with
no specialist title together with family physicians into
'general practices'. A healthcare facility enters into a con-
tract with the NHI in one of 4 categories: academic medi-
cal centre, metropolitan hospital, local community
hospital, or physician clinic.
The data were imported into Microsoft SQL Server 2005
(Microsoft Corp., Redmond, WA, USA) for computation.
The denominator was the number of patients aged 60
years and older who had been insured within the NHI in
2004. Descriptive statistics including means, standard
deviations and percentages were calculated.
Results
At the end of 2004, a total of 2,909,219 beneficiaries aged
60 years and older were insured within the NHI in Tai-
wan: 1,459,513 (50.2%) women, 1,449,688 (49.8%)
men and 22 persons of unknown sex. The average age was
70.9 ± 6.6 years: 72.8 ± 6.8 years for men and 70.2 ± 6.4
years for women. From 73,410,777 ambulatory visits by
the older population in 2004, we identified 35,782
(1.2%) patients receiving intra-articular HA treatment in
205,012 (0.3%) visits.BMC Health Services Research 2008, 8:24 http://www.biomedcentral.com/1472-6963/8/24
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Stratified by age, the highest prevalence of HA use was in
the 70–79 group (1.5%) and the lowest was in the 80
years and older group (1.0%) (Table 1). Women were
more likely to receive intra-articular HA treatment than
men (1.8% vs. 0.7%), especially in the 60–69 (1.6% vs.
0.5%) and 70–79 (2.2% vs. 1.0%) year groups. The gen-
der difference diminished with age.
On average, a patient had 5.7 ± 3.3 visits for intra-articular
HA treatment during the year. Almost half the patients
received the treatment 5 times in the year and 13.8%
received it 10 times. The frequency distribution showed
no marked sex and age differences (Figure 1 and 2).
Most of the intra-articular HA treatment occurred in
orthopaedic (75.1%) and rehabilitation (15.2%) clinics,
and only 1.8% in general practices (Table 2). In all ambu-
latory visits of beneficiaries 60 years and older in 2004,
academic medical centres accounts for 14.8 % visits, met-
ropolitan hospitals for 16.4%, local community hospitals
for 17.5% and physicians clinics for 51.3%. However,
nearly three-quarters of intra-articular HA treatment were
performed in metropolitan hospitals (34.5%) and local
community hospitals (38.2%) (Table 3).
Discussion
Our nationwide survey offered a very rich source of data
concerning intra-articular HA treatment for osteoarthritis
of the knee among the total older population of Taiwan.
Although the prevalence of osteoarthritis of the knee gen-
erally increases with age [14], our study revealed that the
utilization of intra-articular HA treatment in Taiwan did
not fully correlate with the patient's age. People aged
70–79 years tended to receive HA treatment most fre-
quently, and people aged 80 years and older least. This
age-specific pattern of HA use is similar to that of total
knee arthroplasty among osteoarthritic patients. A previ-
ous study showed that the probability of undergoing total
joint arthroplasty increased from 62 to 81 years but fell
after 82 years [15]. Another study found that most of
those aged 75 years and older who might benefit from
knee arthroplasty had not been referred to rheumatologi-
cal or orthopaedic services [16]. Because the oldest people
generally have multiple comorbidities, primary care phy-
sicians might hesitate about referral. As HA treatment has
a low incidence of severe adverse events and good tolera-
bility compared with NSAIDs and corticosteroids
[8,10,11], it might be a relatively safe alternative for the
oldest patients.
Age-specific frequency distribution of visits for intra-articular  hyaluronic acid treatment per patient in 2004 (a total of  205,012 visits by 35,782 patients) Figure 2
Age-specific frequency distribution of visits for intra-articular 
hyaluronic acid treatment per patient in 2004 (a total of 
205,012 visits by 35,782 patients).
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Table 1: Age-sex prevalence and utilization of patients receiving intra-articular hyaluronic acid treatment in 2004
No. of NHI beneficiaries No. of HA patients (%) HA visits per patient in 2004, mean ± SD
Age Male Female Total Male Female Male Female
60–69 710,174 767,070 1,477,244 3,421 (0.5) 12,587 (1.6) 5.6 ± 3.3 5.7 ± 3.1
70–79 547,817 492,487 1,040,664 5,298 (1.0) 10,715 (2.2) 5.7 ± 3.5 5.8 ± 3.4
 80 191,697 199,614 391,311 1,654 (0.9) 2,192 (1.1) 5.6 ± 3.5 5.4 ± 3.2
Sex-specific frequency distribution of visits for intra-articular  hyaluronic acid treatment per patient in 2004 (a total of  205,012 visits by 35,782 patients) Figure 1
Sex-specific frequency distribution of visits for intra-articular 
hyaluronic acid treatment per patient in 2004 (a total of 
205,012 visits by 35,782 patients).
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The prevalence, incidence, symptoms and severity of oste-
oarthritis differ not only with age but also between sexes
[17]. Several studies have shown that women are more
likely than men to have both radiographic and sympto-
matic osteoarthritis of the knee. The female-to-male ratio
for radiographic osteoarthritis of the knee varies from 1.5
to 4.0 [2,14], and that of symptomatic osteoarthritis of the
knee from 1.6 to 1.7 [5,18,19]. In addition, a community
study has shown that the sex difference is more obvious in
the Chinese population [6]. In our study, such a sex differ-
ence existed in the use of intra-articular HA treatment.
This might be due to the difference in disease prevalence
and severity between the sexes. A difference between sexes
in willingness to receive treatment might also play a role.
One study showed that women underwent total knee
arthroplasty at a more advanced stage of their disease [20].
Even with equal willingness to undergo surgery, fewer
women than men had discussed the possibility of arthro-
plasty with a physician though the degree of underuse was
more than three times as great in women as in men [18].
These findings might suggest that women are more
inclined to non-operative treatment or that physicians are
more likely to offer intra-articular HA treatment to
women.
A previous study also showed that the sex difference in the
use of arthroplasty of knee varied with age. Tennant and
colleagues reported that women aged over 55 years made
more demands for knee arthroplasty than men of the
same age and the discrepancy increased with age [16]. In
our study, we found that the sex difference in the use of
intra-articular HA treatment diminished with age. A pos-
sible reason might be the increasing use of arthroplasty
among aged women. The interaction between age and sex
could only be confirmed in longitudinal studies spanning
longer periods. Survey-based studies of patient prefer-
ences may also be needed to help understand whether
patient treatment preferences can explain the gender/age
findings in this study.
In 2004, most of the HA products available within the
NHI in Taiwan were of lower molecular weight. A course
of five injections was suggested to achieve a better clinical
effect. Many patients in our study received intra-articular
HA treatment 5 or 10 times in one year. We might pre-
sume that most patients completed the treatment
course(s), showing good tolerance and adherence to intra-
articular HA. Although its efficacy is currently controver-
sial within academia, HA is generally thought to be more
tolerable than operative procedures and less invasive than
NSAIDs [8,10,11].
In our study, nearly three-quarters of intra-articular HA
treatment occurred in metropolitan hospitals and local
community hospitals, what was disproportionate to the
all visits. The results may reflect either patients' or physi-
cians' preference. Further research may help provide
detailed information.
Our nationwide claims-based study had some limitations.
The one-year cross-sectional survey could not provide
information about trends in intra-articular HA use. The
Table 3: Distribution of visits for intra-articular hyaluronic acid treatment in 2004 by contracted category of healthcare facility
Accreditation level Overall No. of visits (%, n = 
72,665,294)
No. of HA visits (%, n = 205,012) No. of HA patients* (%, n = 
35,872)
Academic medical centres 10,736,652 (14.8) 33,074 (16.1) 6,425 (17.9)
Metropolitan hospitals 11,932,861 (16.4) 70,625 (34.5) 11,760 (32.8)
Local community hospitals 12,730,923 (17.5) 78,268 (38.2) 14,548 (40.6)
Physician clinics 37,264,858 (51.3) 23,045 (11.2) 4,356 (12.1)
*Because a patient might visit several healthcare facilities, the total of all percentages in this column exceeded 100%.
Table 2: Distribution of visits for intra-articular hyaluronic acid treatment in 2004 by specialty
No. of visits (%, n = 205,012) No. of patients* (%, n = 35,872)
Orthopaedics 153,980 (75.1) 27,292 (76.1)
Rehabilitation 31,053 (15.2) 5,323 (14.8)
Rheumatology 7,268 (3.6) 1,399 (3.9)
General surgery 4,180 (2.0) 1,072 (3.0)
General practice 3,666 (1.8) 894 (2.5)
Internal medicine 2,487 (1.2) 621 (1.7)
Neurosurgery 1,067 (0.5) 236 (0.7)
Pain management 952 (0.5) 207 (0.6)
Others 359 (0.2) 96 (0.3)
*Because a patient might visit several specialties, the total of all percentages in this column exceeded 100%.BMC Health Services Research 2008, 8:24 http://www.biomedcentral.com/1472-6963/8/24
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claims contained no data about residence, socio-eco-
nomic background, severity of the disease, functional sta-
tus or the response to treatment. Furthermore, because the
diagnostic coding by ICD-9-CM (the International Classi-
fication of Diseases, Ninth Revision, Clinical Modifica-
tion) in the ambulatory claims was not always precise, we
could not identify all patients with osteoarthritis of the
knee to calculate the prevalence of this condition or the
percentage of patients with HA injections among all
patients suffering from it.
Conclusion
The high usage and completion rates of intra-articular HA
treatment reflected high tolerance of the treatment in ger-
iatric ambulatory care. Further research is needed to eluci-
date the effectiveness and adverse effects of this important
osteoarthritic knee treatment in the elderly population.
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